Gili Kenet, MD

Director
The National Hemophilia Center, and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel

Prof Gili Kenet is pediatric Hematologist, director of the Israeli National Hemophilia Center in Sheba Medical Center, Tel Hashomer, and the head of the Amalia Biron Thrombosis Reserach Institute of Tel Aviv University .
Professor Kenet is the author of over 260 peer reviewed scientific publications, review articles and book chapters. She is an active member of WFH and ISTH, a former Chairperson of the Pediatric and Peri-natal Hemostasis SSC and co- chair of the FVIII/ FIX/ RBD SSC of ISTH.

Presentation(s):

• SS 13.3 - Improving the Service: Understanding Unmet Needs in Quality of Life and Activity

  Sunday, July 10, 2022
  1:40 PM – 2:00 PM

• LB 01.1 - A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

  Sunday, July 10, 2022
  2:45 PM – 3:00 PM

• LB 01.3 - Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, July 10, 2022
  3:15 PM – 3:30 PM

• OC 27.1 - The type and frequency of bleeds in 870 children with severe hemophilia A and B on primary prophylaxis: Data from the PedNet study group

  Sunday, July 10, 2022
  2:45 PM – 3:00 PM

• PB0046 - Association between thrombin generation and clinical characteristics in COVID-19 patients

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0237 - Bleeding assesment in children with Noonan syndrome

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0260 - Comparison of heparin-induced thrombocytopenia workup and clinical characteristics between pediatric and adult patients

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0662 - Clinical Study of Adenovirus-Associated Viral Vector-Mediated Gene Therapy of Human Factor VIII in Severe and Moderately Severe Hemophilia A

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 50.2 - Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B Without inhibitors

  Tuesday, July 12, 2022
  11:00 AM – 11:15 AM

• PB1085 - Laboratory versus point-of-care INR testing in patients with lupus anticoagulant – a retrospective cohort analysis

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1178 - Praxbind for reversal of Dabigatran: experience in a tertiary hospital

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM